Skip to content

Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03796104
Enrollment
100
Registered
2019-01-08
Start date
2018-01-01
Completion date
2023-12-31
Last updated
2023-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and Joint Infection, Staphylococcus Aureus

Keywords

Bone and Joint Infection, Staphylococcus Aureus, chronic infection

Brief summary

The aim of this study is to determine if delta-haemolysin production deficiency of Staphylococcus aureus is a marker in favour of chronic infections on implants

Interventions

OTHERDelta-haemolysin

comparison of groups having infection with S. aureus with and without delta-haemolysin Production

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years

Inclusion criteria

* patients having implant infection due to S. aureus treated by DAIR

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Rate of infection with or witout delta-haemolysin in Staphylococcus AureusOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruptionpatients, profile of the bacterium, medical and chirurgical treatment, rate. comparison between the 2 groups

Secondary

MeasureTime frameDescription
Rate of Treatment FailureOutcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruptionTreatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor. Comparison between the 2 groups

Countries

France

Contacts

Primary ContactJohanna Boulant, CRA
johanna.boulant@chu-lyon.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026